Anticoagulation Options in Patients with Renal Disease

Introduction to Anticoagulation Therapy

The European Society of Cardiology recommends that in patients with severe renal insufficiency, fondaparinux could be the anticoagulant of choice due to its demonstrated lower risk of hemorrhagic complications compared to enoxaparina, even in patients with severe renal impairment 1, 2
In patients with severe renal insufficiency (CrCl <30 mL/min), low molecular weight heparins (LMWH) are contraindicated or require dose adjustment according to country-specific guidelines 2

Enoxaparina requires dose adjustment in severe renal insufficiency, as it can accumulate and increase the risk of bleeding 3, 4
Dalteparina and tinzaparina may have less accumulation in renal insufficiency but should be used with caution 4
The risk of bleeding with LMWH can be up to twice as high in patients with creatinine clearance <30 mL/min 3
Monitoring of anti-Xa levels is recommended when using LMWH in patients with moderate to severe renal insufficiency 3
Fondaparinux, although formally contraindicated in severe renal insufficiency (CrCl <30 mL/min), has demonstrated a lower risk of hemorrhagic complications compared to enoxaparina in patients with severe renal insufficiency 1, 2
Fondaparinux could be considered the anticoagulant of choice in this situation due to its favorable safety profile 2
Bivalirudin should have its infusion rate reduced to 1.0 mg/kg/h in patients with CrCl <30 mL/min, and to 0.25 mg/kg/h in patients on hemodialysis 2

Tirofiban requires dose adjustment in renal insufficiency, with only 50% of the dose administered if CrCl <30 mL/min 2
Eptifibatide is eliminated 50% via the renal route, and in patients with CrCl <50 mL/min, the infusion dose should be reduced to 1 mg/kg/min, with the bolus dose remaining unchanged; it is contraindicated in patients with CrCl <30 mL/min 2
Abciximab has no specific dose adjustment recommendations for renal insufficiency but requires careful evaluation of the hemorrhagic risk 2

Antagonists of Vitamin K (AVK) are a safer option for long-term treatment in patients with severe renal insufficiency 3
Direct Oral Anticoagulants (DOACs) have shown to be non-inferior and relatively safe compared to conventional anticoagulants in patients with renal insufficiency, although specific details are not provided in the cited references

Patients with chronic kidney disease and CrCl <60 mL/min are at high risk of ischemic events and should undergo invasive evaluation and revascularization whenever possible 2
Pre- and post-hydration for angiography and/or angioplasty is the strategy that has shown the greatest impact in reducing the risk of contrast-induced nephropathy 1
The amount of contrast medium should be limited to a maximum of 50 mL for a diagnostic procedure 2
Evaluation of creatinine levels up to day 3 after contrast injection is necessary to detect contrast-induced nephropathy 2